Juha Koskenvuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juha Koskenvuo has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
Tero-Pekka Alastalo
11 shared publications- Juhani Knuuti
Turku PET Centre, University of Turku, Turku, Finland
6 shared publications - Inka Saarinen
Senior Manager, Data Services BioPharma/Blueprint Genetics
5 shared publications - Johanna Sistonen
Genome Unit, HUS Diagnostic Center Helsinki University Hospital Helsinki Finland
5 shared publications Kim Gall
5 shared publicationsMassimiliano Gentile
Informatics Director/Blueprint Genetics
5 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3552
Phenotypic Heterogeneity in Titinopathies with Peripheral Nerve Involvement in Pediatric Age: Two Case Reports
Background/Objectives: Titin (TTN; OMIM 188840) is the largest known human sarcomeric protein, and pathogenic variants in the TTN gene cause a broad spectrum of inherited myopathies and cardiomyopathies. The extent to which TTN variants may also involve the peripheral nervous system remains poorly defined. We aimed to describe two pediatric patients carrying heterozygous truncating TTN variants with neurophysiological evidence of peripheral nerve involvement, and to review the existing literature on this underrecognized association. Pathogenic variants in the TTN gene are associated with a wide spectrum of inherited myopathies and cardiomyopathies. To date, peripheral neur opathy has not been recognized as a defining feature of TTN-related disorders, and neurophysiological investigations in affected individuals typically demonstrate normal or myopathic findings without evidence of a primary neuropathic process. Here, we report two pediatric patients with heterozygous truncating TTN variants and neurophysiological evidence of bilateral axonal involvement of the deep peroneal nerve. Methods: This case report was structured and reported according to the CARE guidelines. Genetic testing was performed using whole-exome sequencing (Blueprint Genetics Whole Exome Family Test). Nerve conduction studies and needle electromyography were performed using the Galileo NT system. Variant classification followed current ACMG guidelines. Results: The first patient, a 10-year-old girl, presented with a symptomatic distal motor phenotype characterized by bilateral pes cavus, anterior compartment muscle atrophy, areflexia, and steppage gait with onset in early childhood. The second patient, an 8-year-old boy, had subclinical bilateral axonal neuropathy identified during neurophysiological evaluation prompted by intermittent lower limb pain; his father, carrying the same variant, showed concordant neurophysiological abnormalities. In both cases, nerve conduction studies demonstrated reduced compound muscle action potential amplitudes with preserved conduction velocities and distal latencies, consistent with axonal neuropathy. Whole-exome sequencing excluded other established genetic causes of inherited neuropathy in both probands. Conclusions: Although a causal relationship cannot be established, these observations raise the possibility that peripheral nerve involvement may represent an underrecognized feature of the titinopathy spectrum. Prospective studies in larger cohorts of TTN variant carriers are needed to clarify the prevalence and pathophysiological basis of neuropathy in this context.
- 6 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3552
Open AccessPhenotypic Heterogeneity in Titinopathies with Peripheral Nerve Involvement in Pediatric Age: Two Case Reports
Background/Objectives: Titin (TTN; OMIM 188840) is the largest known human sarcomeric protein, and pathogenic variants in the TTN gene cause a broad spectrum of inherited myopathies and cardiomyopathies. The extent to which TTN variants may also involve the peripheral nervous system remains poorly defined. We aimed to describe two pediatric patients carrying heterozygous truncating TTN variants with neurophysiological evidence of peripheral nerve involvement, and to review the existing literature on this underrecognized association. Pathogenic variants in the TTN gene are associated with a wide spectrum of inherited myopathies and cardiomyopathies. To date, peripheral neur opathy has not been recognized as a defining feature of TTN-related disorders, and neurophysiological investigations in affected individuals typically demonstrate normal or myopathic findings without evidence of a primary neuropathic process. Here, we report two pediatric patients with heterozygous truncating TTN variants and neurophysiological evidence of bilateral axonal involvement of the deep peroneal nerve. Methods: This case report was structured and reported according to the CARE guidelines. Genetic testing was performed using whole-exome sequencing (Blueprint Genetics Whole Exome Family Test). Nerve conduction studies and needle electromyography were performed using the Galileo NT system. Variant classification followed current ACMG guidelines. Results: The first patient, a 10-year-old girl, presented with a symptomatic distal motor phenotype characterized by bilateral pes cavus, anterior compartment muscle atrophy, areflexia, and steppage gait with onset in early childhood. The second patient, an 8-year-old boy, had subclinical bilateral axonal neuropathy identified during neurophysiological evaluation prompted by intermittent lower limb pain; his father, carrying the same variant, showed concordant neurophysiological abnormalities. In both cases, nerve conduction studies demonstrated reduced compound muscle action potential amplitudes with preserved conduction velocities and distal latencies, consistent with axonal neuropathy. Whole-exome sequencing excluded other established genetic causes of inherited neuropathy in both probands. Conclusions: Although a causal relationship cannot be established, these observations raise the possibility that peripheral nerve involvement may represent an underrecognized feature of the titinopathy spectrum. Prospective studies in larger cohorts of TTN variant carriers are needed to clarify the prevalence and pathophysiological basis of neuropathy in this context.
- Open Access
- 27 May 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (6) , 1558
The Junctophilin-2 Mutation p.(Thr161Lys) Is Associated with Hypertrophic Cardiomyopathy Using Patient-Specific iPS Cardiomyocytes and Demonstrates Prolonged Action Potential and Increased Arrhythmogenicity
Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiac diseases; it is primarily caused by mutations in sarcomeric genes. However, HCM is also associated with mutations in non-sarcomeric proteins and a Finnish founder mutation for HCM in non-sarcomeric protein junctophilin-2 (JPH2) has been identified. This study aimed at assessing the issue of modelling the rare Finnish founder mutation in cardiomyocytes (CMs) differentiated from iPSCs; therefore, presenting the same cardiac abnormalities observed in the patients. To explore the abnormal functions in JPH2-HCM, skin fibroblasts from a Finnish patient with JPH2 p.(Thr161Lys) were reprogrammed into iPSCs and further differentiated into CMs. As a control line, an isogenic counterpart was generated using the CRISPR/Cas9 genome editing method. Finally, iPSC-CMs were evaluated for the morphological and functional characteristics associated with JPH2 mutation. JPH2-hiPSC-CMs displayed key HCM hallmarks (cellular hypertrophy, multi-nucleation, sarcomeric disarray). Moreover, JPH2-hiPSC-CMs exhibit a higher degree of arrhythmia and longer action potential duration associated with slower inactivation of calcium channels. Functional evaluation supported clinical observations, with differences in beating characteristics when compared with isogenic-hiPSC-CMs. Thus, the iPSC-derived, disease-specific cardiomyocytes could serve as a translationally relevant platform to study genetic cardiac diseases.
- 27 May 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (6) , 1558
Open AccessThe Junctophilin-2 Mutation p.(Thr161Lys) Is Associated with Hypertrophic Cardiomyopathy Using Patient-Specific iPS Cardiomyocytes and Demonstrates Prolonged Action Potential and Increased Arrhythmogenicity
Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiac diseases; it is primarily caused by mutations in sarcomeric genes. However, HCM is also associated with mutations in non-sarcomeric proteins and a Finnish founder mutation for HCM in non-sarcomeric protein junctophilin-2 (JPH2) has been identified. This study aimed at assessing the issue of modelling the rare Finnish founder mutation in cardiomyocytes (CMs) differentiated from iPSCs; therefore, presenting the same cardiac abnormalities observed in the patients. To explore the abnormal functions in JPH2-HCM, skin fibroblasts from a Finnish patient with JPH2 p.(Thr161Lys) were reprogrammed into iPSCs and further differentiated into CMs. As a control line, an isogenic counterpart was generated using the CRISPR/Cas9 genome editing method. Finally, iPSC-CMs were evaluated for the morphological and functional characteristics associated with JPH2 mutation. JPH2-hiPSC-CMs displayed key HCM hallmarks (cellular hypertrophy, multi-nucleation, sarcomeric disarray). Moreover, JPH2-hiPSC-CMs exhibit a higher degree of arrhythmia and longer action potential duration associated with slower inactivation of calcium channels. Functional evaluation supported clinical observations, with differences in beating characteristics when compared with isogenic-hiPSC-CMs. Thus, the iPSC-derived, disease-specific cardiomyocytes could serve as a translationally relevant platform to study genetic cardiac diseases.
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 16
Genetic Findings from a Multigene Panel for Autoinflammatory Disease
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 16
Genetic Findings from a Multigene Panel for Autoinflammatory Disease
- Open Access
- 16 March 2022
- Published by MDPI AG in Cardiogenetics
- Vol. 12 (1) , 122-132
MYH7 Genotype–Phenotype Correlation in a Cohort of Finnish Patients
Cardiomyopathies (CMPs) are a heterogeneous group of diseases, frequently genetic, affecting the heart muscle. The symptoms range from asymptomatic to dyspnea, arrhythmias, syncope, and sudden cardiac death. This study is focused on MYH7 (beta-myosin heavy chain), as this gene is commonly mutated in cardiomyopathy patients. Due to the high combined prevalence of MYH7 variants and severe health outcomes, it is one of the most frequently tested genes in clinical settings. We analyzed the clinical presentation and natural history of 48 patients with MYH7-related cardiomyopathy belonging to a cohort from a tertiary center at Helsinki University Hospital, Finland. We made special reference to three age subgroups (0–1, 1–12, and >12 years). Our results characterize a clinically significant MYH7 cohort, emphasizing the high variability of the CMP phenotype depending on age. We observed a subgroup of infants (0–1 years) with MYH7 associated severe DCM phenotype. We further demonstrate that patients under the age of 12 years have a similar symptom burden compared to older patients.
- 16 March 2022
- Published by MDPI AG in Cardiogenetics
- Vol. 12 (1) , 122-132
Open AccessMYH7 Genotype–Phenotype Correlation in a Cohort of Finnish Patients
Cardiomyopathies (CMPs) are a heterogeneous group of diseases, frequently genetic, affecting the heart muscle. The symptoms range from asymptomatic to dyspnea, arrhythmias, syncope, and sudden cardiac death. This study is focused on MYH7 (beta-myosin heavy chain), as this gene is commonly mutated in cardiomyopathy patients. Due to the high combined prevalence of MYH7 variants and severe health outcomes, it is one of the most frequently tested genes in clinical settings. We analyzed the clinical presentation and natural history of 48 patients with MYH7-related cardiomyopathy belonging to a cohort from a tertiary center at Helsinki University Hospital, Finland. We made special reference to three age subgroups (0–1, 1–12, and >12 years). Our results characterize a clinically significant MYH7 cohort, emphasizing the high variability of the CMP phenotype depending on age. We observed a subgroup of infants (0–1 years) with MYH7 associated severe DCM phenotype. We further demonstrate that patients under the age of 12 years have a similar symptom burden compared to older patients.
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S59
Diagnostic yield and clinical utility of genetic testing in children with seizure onset after 2 years of age: an update
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S59
Diagnostic yield and clinical utility of genetic testing in children with seizure onset after 2 years of age: an update
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S233-S234
Retrospective review of genetic testing for inherited bone marrow failure syndromes
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S233-S234
Retrospective review of genetic testing for inherited bone marrow failure syndromes
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S229
Retrospective review of mitochondrial genome analysis in over 7000 patients using clinical grade mtDNA sequencing
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S229
Retrospective review of mitochondrial genome analysis in over 7000 patients using clinical grade mtDNA sequencing
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S220
Biallelic NRAP variants are a significant cause of dilated cardiomyopathy
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S220
Biallelic NRAP variants are a significant cause of dilated cardiomyopathy
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S221
Next-generation sequencing panels for hereditary hearing loss testing with approaches for difficult-to-sequence regions
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S221
Next-generation sequencing panels for hereditary hearing loss testing with approaches for difficult-to-sequence regions
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S221-S222
Diagnostic utility of next-generation sequencing panel tests in the diagnosis of skeletal dysplasias
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S221-S222
Diagnostic utility of next-generation sequencing panel tests in the diagnosis of skeletal dysplasias